Leave a comment

FierceBiotech Special Report: China’s Rise Drives Investment in Biotech Drugs

Until recently, the history of the pharmaceutical industry in China was more about imitation than innovation.

According to a report by London-based market researcher Scrip Intelligence, approximately 40% of biotech sales in China come from biosimilars. This would explain why the market for biologics in China has been growing at a rate of more than 25% a year, while total sales of biotech drugs are still only $1.5 billion a year.  Read more

Leave a comment

Overview of Chinese Biotech Market and Opportunities – Gao RongHui

Gao RongHui has recently visited the bioXclusters regions where he has had the opportunity to learn about its different organisations and present the Chinese market  to cluster company members in workshops.

Gao RongHui is a senior consultant specialised in life sciences, based in Shanghai. During his trip to Europe, he GaoRonghuivisited the four bioXclusters’ regions: Bavaria, Catalonia, Piedmont and Rhône-Alpes where he spoke about the opportunities of the biotech, biomedical and medtech sectors in China.

Continue reading

Leave a comment

China – the next major innovative pharma market? by Bioassociate

This recently published report explores regulatory shifts in China, the capacity of the country to embrace innovation, the highly fragmented industry’s kBioassociate-China-Next-Innovative-Pharma-Market-206x300ey leaders and other relevant issues for a better understanding of the market and identification of key trends for the future. Click here for the download


Leave a comment

Things you have to know about Regulatory Issues in China

There’s no question that China is an appealing market for the biotech industry. This is not only because of the possibilities it offers for lowering  R&D costs, but also because of its market size. Demographics are a reason for this country’s attractiveness: a large and progressively wealthier population that is getting older represents a  new market of potential users of biotech products.

But investing in China is not an easy process. The lack of transparency and the challenges related to regulatory issues make the process long and difficult, in addition to the maze of authorities involved. Continue reading